🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

UK-based BenevolentAI to cut about 180 jobs as part of restructuring plan

Published 28-05-2023, 07:45 pm
UK-based BenevolentAI to cut about 180 jobs as part of restructuring plan

London, May 28 (IANS) UK-based AI drug discovery company BenevolentAI has announced to lay off about 180 employees as part of a restructuring plan that resulted from a strategic review, while CFO (Chief Financial Officer) Nicholas Keher has resigned.

According to BusinessCloud, the company will streamline and reorganise operations across two business units -- the Tech Business Unit and the Bio Business Unit, as part of a strategic reorganisation.

The reorganisation is projected to generate net cost savings of 45 million pounds, which includes 13 million pounds from facilities and other operating expenses, as well as 32 million pounds in savings from reduced drug programme and staff costs.

These savings are expected to extend the company's cash runway until at least July 2025, without accounting for any new revenues.

"Embarking on this process requires difficult decisions, particularly concerning our valued colleagues," CEO Joanna Shields was quoted as saying.

"Our new strategic direction ensures we maximise our portfolio and leverage the knowledge and expertise we have built up in recent years to meet this moment of opportunity for AI in biopharma," she added.

As part of its strategic plan, the company may develop a new suite of revenue-generating products to capitalise on the vast potential of AI-driven technologies in the biopharma domain, the report said.

Meanwhile, leading biotechnology company Twist Bioscience Corporation has announced to lay off 270 people, or about 25 per cent of its workforce, as it aims to accelerate its path to profitability.

The company enables customers to succeed through its offering of high-quality synthetic DNA using its silicon platform.

--IANS

shs/svn/

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.